« Return to News | Drug Sponsors

Japan Chooses Sanofi Pasteur for First Enhanced Inactivated Polio Vaccine

Friday, May 4, 2012 08:00 AM

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Sanofi Pasteur’s, standalone Inactivated Poliovirus Vaccine (IPV) against acute flaccid poliomyelitis (Imovax Polio). Imovax Polio will be added to the country's public immunization program on September 1.

Since 1988, start of the Global Polio Eradication Initiative led by the World Health Organization (WHO) and its partners, the number of polio cases has been reduced by 99% worldwide.  The approval of Imovax Polio by Japanese health authorities is another step towards a polio-free world. Imovax Polio is an inactivated poliovirus vaccine made from poliovirus types 1, 2 and 3. Since its launch in France in 1982, Imovax Polio has been approved in 86 countries. Sanofi Pasteur has supplied more than 800 million doses of standalone IPV and IPV-containing combination vaccines worldwide to date.

"Inactivated poliovirus vaccine is the standard of care for polio vaccination in polio-free countries. Sanofi Pasteur is committed to doing its utmost to contribute to protecting as many infants as possible in Japan from polio," said Olivier Charmeil, president and CEO of Sanofi Pasteur.

In the past, Japan had immunized its population with Oral Poliovirus Vaccine (OPV), starting in 1961.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.